Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Shares Outstanding (Weighted Average) (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Shares Outstanding (Weighted Average) for 4 consecutive years, with $72.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 15.42% to $72.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $72.9 million through Dec 2025, up 15.42% year-over-year, with the annual reading at $72.9 million for FY2025, 15.42% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $72.9 million at Phathom Pharmaceuticals, roughly flat from $72.6 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $72.9 million in Q4 2025, with the low at $38.0 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 4 years is $55.5 million, with a median of $57.6 million recorded in 2023.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 46.27% in 2023, while the deepest fall reached 11.35% in 2023.
  • Over 4 years, Shares Outstanding (Weighted Average) stood at $39.1 million in 2022, then surged by 31.11% to $51.3 million in 2023, then rose by 23.18% to $63.2 million in 2024, then rose by 15.42% to $72.9 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $72.9 million, $72.6 million, and $72.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.